Evaluation of Prognostic Factors in Adult Sinonasal Rhabdomyosarcoma With Consideration of Resection Status
Otolaryngology–Head and Neck Surgery · 2026-08 · 175 (2) · 394-401
DOI: 10.1002/ohn.70271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, online erschienen am 29.05.2026. Verfasst von Junlin Yi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sci…. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Paranasal Sinus Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To evaluate R0 resection's prognostic significance and its association with induction chemotherapy (ICT) response in adult sinonasal rhabdomyosarcoma (SNRMS). Study Design Retrospective study.
Setting
Beijing Tongren Hospital and the National Cancer Hospital.
Methods
Fifty‐one patients who met the inclusion criteria were identified through chart review. Patients were divided into 3 groups: a nonsurgical group and 2 surgical groups, 1 with a R0 resection and one with a positive margin. Overall survival (OS) and progression‐free survival (PFS) were calculated using the Kaplan‐Meier analysis. The Log‐rank test and Cox regression analysis were performed to evaluate prognostic factors. The chi‐square test was used to analyze associations.
Results
No differences in characteristics were observed among the groups. Patients with R0 resection had significantly higher OS and PFS than those with positive margins or nonsurgical (OS: P = .001, P = .016, respectively; PFS: P < .001, P = .005, respectively). There was no significant difference in OS or PFS between positive margins and nonsurgical group ( P = .163, P = .059, respectively). Multivariate analysis revealed that R0 resection was an independent risk factor for OS (HR = 0.224, 95% CI: 0.079‐0.639, P = .005). The R0 resection rate was significantly higher in the positive ICT response group than in the negative response group and the non‐ICT group ( χ ² = 7.119, df = 2, P = .028).
Conclusion
The overall treatment strategy for adult SNRMS should focus on achieving local tumor control through comprehensive, multidisciplinary treatment to achieve R0 resection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Radiation Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/ Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.
- Department of Otolaryngology Head and Neck Surgery, Fu Xing Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Xiaohong Chen
Zitieren
APA
Yi, J., Cao, L., Zhang, J. H., Bai, Y., & Chen, X. (2026). Evaluation of Prognostic Factors in Adult Sinonasal Rhabdomyosarcoma With Consideration of Resection Status. Otolaryngology–Head and Neck Surgery, 175(2), 394-401. https://doi.org/10.1002/ohn.70271
Vancouver
Yi J, Cao L, Zhang JH, Bai Y, Chen X. Evaluation of Prognostic Factors in Adult Sinonasal Rhabdomyosarcoma With Consideration of Resection Status. Otolaryngology–Head and Neck Surgery. 2026;175(2):394-401. doi:10.1002/ohn.70271
BibTeX
@article{Yi2026,
author = {Yi, Junlin and Cao, Lili and Zhang, Jiang-Hu and Bai, Yunlong and Chen, Xiaohong},
title = {Evaluation of Prognostic Factors in Adult Sinonasal Rhabdomyosarcoma With Consideration of Resection Status},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2026},
volume = {175},
number = {2},
pages = {394--401},
doi = {10.1002/ohn.70271}
}
EUVIMED